Compare Stocks

Date Range: 

 Zynerba PharmaceuticalsStrongbridge BiopharmaHeat BiologicsAntibe TherapeuticsMarker Therapeutics
SymbolNASDAQ:ZYNENASDAQ:SBBPNASDAQ:HTBXOTCMKTS:ATBPFNASDAQ:MRKR
Price Information
Current Price$4.17$2.42$6.29$3.54$2.24
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.31.51.61.71.5
Analysis Score3.43.53.53.53.4
Community Score2.72.33.04.42.5
Dividend Score0.00.00.00.00.0
Ownership Score0.00.80.80.01.7
Earnings & Valuation Score0.60.60.60.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$13.65$7.50$18.00$7.95$8.67
% Upside from Price Target227.34% upside209.92% upside186.17% upside124.58% upside286.90% upside
Trade Information
Market Cap$172.02 million$163.46 million$158.84 million$161.42 million$177.64 million
Beta2.831.910.320.561.27
Average Volume4,296,470946,2611,867,31944,5912,882,491
Sales & Book Value
Annual Revenue$90,000.00$21.71 million$3.05 million$7.51 million$210,000.00
Price / Sales1,911.347.5352.0821.49845.90
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$3.26 per share$1.33 per share$2.73 per share$0.10 per share$0.96 per share
Price / Book1.281.822.3035.402.33
Profitability
Net Income$-32,940,000.00$-49,450,000.00$-20,020,000.00$-14,540,000.00$-21,430,000.00
EPS($1.50)($1.10)N/A($0.50)($0.47)
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-149.79%-527.90%-273.96%N/A
Return on Equity (ROE)-60.20%-65.85%-44.07%-150.49%-68.00%
Return on Assets (ROA)-52.40%-38.81%-36.38%-98.51%-54.26%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.10%N/AN/AN/A
Current Ratio6.54%4.51%31.34%5.97%5.03%
Quick Ratio6.54%4.45%31.34%5.42%5.03%
Ownership Information
Institutional Ownership Percentage25.99%58.27%49.84%N/A29.42%
Insider Ownership Percentage11.10%6.60%5.50%N/A30.90%
Miscellaneous
Employees2672394744
Shares Outstanding41.25 million67.55 million25.25 million45.60 million79.30 million
Next Earnings DateN/A5/12/2021 (Confirmed)8/6/2021 (Estimated)7/23/2021 (Estimated)5/12/2021 (Confirmed)
OptionableOptionableOptionableNot OptionableNot OptionableOptionable
SourceHeadline
Insiders are Buying These 3 Stocks - Should You? (MRKR)Insiders are Buying These 3 Stocks - Should You? (MRKR)
insidertrades.com - May 10 at 4:41 PM
Marker Therapeutics, Inc. Forecasted to Post FY2022 Earnings of ($0.37) Per Share (NASDAQ:MRKR)Marker Therapeutics, Inc. Forecasted to Post FY2022 Earnings of ($0.37) Per Share (NASDAQ:MRKR)
americanbankingnews.com - May 9 at 3:36 AM
Marker Recognizing Lynching in Columbia VandalizedMarker Recognizing Lynching in Columbia Vandalized
usnews.com - May 8 at 2:19 PM
Analysts Advise You To Build Your Position In Marker Therapeutics, Inc. (NASDAQ:MRKR)Analysts Advise You To Build Your Position In Marker Therapeutics, Inc. (NASDAQ:MRKR)
stocksregister.com - May 7 at 6:47 PM
Analysts Set Expectations for Marker Therapeutics, Inc.s FY2022 Earnings (NASDAQ:MRKR)Analysts Set Expectations for Marker Therapeutics, Inc.'s FY2022 Earnings (NASDAQ:MRKR)
americanbankingnews.com - May 7 at 11:36 AM
Marker Therapeutics (MRKR) Set to Announce Earnings on WednesdayMarker Therapeutics (MRKR) Set to Announce Earnings on Wednesday
americanbankingnews.com - May 5 at 7:34 AM
Marker Therapeutics (MRKR) to Release Earnings on WednesdayMarker Therapeutics (MRKR) to Release Earnings on Wednesday
americanbankingnews.com - May 5 at 7:34 AM
Marker Therapeutics Inc. (NASDAQ:MRKR) surprises Wall Street with -4.48% stock price lossMarker Therapeutics Inc. (NASDAQ:MRKR) surprises Wall Street with -4.48% stock price loss
marketingsentinel.com - May 3 at 2:12 PM
What lies ahead for Marker Therapeutics, Inc. (NASDAQ:MRKR) In 2020What lies ahead for Marker Therapeutics, Inc. (NASDAQ:MRKR) In 2020
stocksregister.com - April 30 at 8:15 AM
Zacks: Analysts Anticipate Marker Therapeutics, Inc. (NASDAQ:MRKR) to Announce -$0.16 EPSZacks: Analysts Anticipate Marker Therapeutics, Inc. (NASDAQ:MRKR) to Announce -$0.16 EPS
americanbankingnews.com - April 29 at 10:34 PM
Marker Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast on Wednesday, May 12, 2021Marker Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast on Wednesday, May 12, 2021
finance.yahoo.com - April 29 at 5:13 PM
Thinking about buying stock in Hall of Fame Resort & Entertainment, Marker Therapeutics, LendingClub, Smith & Nephew, or Clover Health Investments?Thinking about buying stock in Hall of Fame Resort & Entertainment, Marker Therapeutics, LendingClub, Smith & Nephew, or Clover Health Investments?
benzinga.com - April 29 at 12:11 PM
Marker Therapeutics, Inc. (NASDAQ:MRKR): How Much Is It Worth And What Should Investors Do?Marker Therapeutics, Inc. (NASDAQ:MRKR): How Much Is It Worth And What Should Investors Do?
marketingsentinel.com - April 29 at 12:11 PM
Historic Marker Day targets maintenance of signs'Historic Marker Day' targets maintenance of signs
news.yahoo.com - April 28 at 10:46 AM
‘Historic Marker Day’ targets maintenance of signs‘Historic Marker Day’ targets maintenance of signs
thedailynewsonline.com - April 28 at 5:46 AM
Marker Therapeutics to Present Multi-Tumor-...Marker Therapeutics to Present Multi-Tumor-...
benzinga.com - April 27 at 10:45 PM
Analysts believe Marker Therapeutics, Inc. (NASDAQ:MRKR)’s share price will rise 214.96% from current levelsAnalysts believe Marker Therapeutics, Inc. (NASDAQ:MRKR)’s share price will rise 214.96% from current levels
stocksregister.com - April 27 at 12:44 PM
Global Cardiac Marker Tests (In Vitro Diagnostics) Market Analysis and Forecast Model with COVID-19 Market Impact, 2015-2020 & 2020-2030 - ResearchAndGlobal Cardiac Marker Tests (In Vitro Diagnostics) Market Analysis and Forecast Model with COVID-19 Market Impact, 2015-2020 & 2020-2030 - ResearchAnd
us.acrofan.com - April 26 at 4:39 PM
Marker Therapeutics (NASDAQ:MRKR) & Xencor (NASDAQ:XNCR) Head-To-Head ContrastMarker Therapeutics (NASDAQ:MRKR) & Xencor (NASDAQ:XNCR) Head-To-Head Contrast
americanbankingnews.com - April 24 at 4:26 AM
Market Analysts see Marker Therapeutics Inc. [MRKR] gaining to $6. Time to buy?Market Analysts see Marker Therapeutics Inc. [MRKR] gaining to $6. Time to buy?
dbtnews.com - April 23 at 1:17 AM
Marker Therapeutics, Inc. (NASDAQ:MRKR) Given Consensus Rating of "Buy" by AnalystsMarker Therapeutics, Inc. (NASDAQ:MRKR) Given Consensus Rating of "Buy" by Analysts
americanbankingnews.com - April 22 at 2:34 AM
Here’s Why Marker Therapeutics, Inc. (NASDAQ:MRKR) is an Attractive Pick for Investors NowHere’s Why Marker Therapeutics, Inc. (NASDAQ:MRKR) is an Attractive Pick for Investors Now
stocksregister.com - April 20 at 2:50 PM
Top 10 Best Bic Marker Sets 2021Top 10 Best Bic Marker Sets 2021
bestgamingpro.com - April 20 at 9:49 AM
Marker Therapeutics, Inc. (NASDAQ:MRKR) Stock Forecast for 2021: Bullish Signs Point to $8 per ShareMarker Therapeutics, Inc. (NASDAQ:MRKR) Stock Forecast for 2021: Bullish Signs Point to $8 per Share
marketingsentinel.com - April 19 at 8:32 AM
SDSU claims Dakota Marker title, top seed in FCS playoffsSDSU claims Dakota Marker title, top seed in FCS playoffs
rapidcityjournal.com - April 18 at 5:09 PM
DateCompanyBrokerageAction
5/6/2021Zynerba PharmaceuticalsCantor FitzgeraldBoost Price Target
3/10/2021Zynerba PharmaceuticalsRoth CapitalLower Price Target
2/5/2021Zynerba PharmaceuticalsCanaccord GenuityReiterated Rating
12/21/2020Zynerba PharmaceuticalsHC WainwrightLower Price Target
9/14/2020Zynerba PharmaceuticalsNeedham & Company LLCReiterated Rating
6/29/2020Zynerba PharmaceuticalsLADENBURG THALM/SH SHReiterated Rating
9/16/2019Zynerba PharmaceuticalsJefferies Financial GroupReiterated Rating
5/6/2020Strongbridge BiopharmaOppenheimerReiterated Rating
3/3/2020Strongbridge BiopharmaCraig HallumInitiated Coverage
9/24/2019Strongbridge BiopharmaEvercore ISIInitiated Coverage
12/18/2018Strongbridge BiopharmaLaidlawInitiated Coverage
8/9/2018Strongbridge BiopharmaJMP SecuritiesBoost Price Target
8/8/2018Strongbridge BiopharmaJanney Montgomery ScottBoost Price Target
5/6/2021Heat BiologicsAlliance Global PartnersLower Price Target
2/9/2021Heat BiologicsMaxim GroupReiterated Rating
12/24/2020Heat BiologicsB. RileyReiterated Rating
7/29/2019Heat BiologicsBrookline Capital ManagementInitiated Coverage
7/9/2018Heat BiologicsEurobank EFGInitiated Coverage
9/4/2020Antibe TherapeuticsEchelon Wealth PartnersReiterated Rating
3/31/2021Marker TherapeuticsPiper SandlerInitiated Coverage
6/24/2020Marker TherapeuticsNomuraReiterated Rating
11/13/2019Marker TherapeuticsPiper Jaffray CompaniesLower Price Target
8/13/2019Marker TherapeuticsNomura SecuritiesReiterated Rating
3/29/2019Marker TherapeuticsWBB SecuritiesUpgrade
(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.